CAS Registry Number is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-19. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
recognition site A specific motif or sequence, either of nucleotides in a nucleic acid molecule or of amino acids in a protein, that is "recognized" or identified by another protein in order to direct the protein's activity to a specific molecule or location. Recognition motifs may consist of a simple consecutive sequence within a single molecule or may involve multiple non-consecutive motifs, e.g. amino acids in separate parts of the same polypeptide which are brought into juxtaposition by the quaternary structure created during protein folding. Recognition sites often help to distinguish the nucleic acid or protein bearing the motif from other similar molecules and thereby identify it as a valid target for some biochemical activity, or to specify a locus or subregion within the larger macromolecule at which the activity is to occur. In this sense recognition sites are critical for properly localizing proteins to their biochemical targets. A protein's recognition site is often but not necessarily the same as its binding site or target site.
In many MHD systems, most of the electric current is compressed into thin, nearly two-dimensional ribbons termed current sheets. These can divide the fluid into magnetic domains within which the currents are relatively weak. Current sheets in the solar corona are thought to be between a few meters and a few kilometers thick, which is quite thin compared to the magnetic domains, which are thousands to hundreds of thousands of kilometers across. Another example occurs in the Earth's magnetosphere, where current sheets separate topologically distinct domains, isolating most of the Earth's ionosphere from the solar wind.
=== Binding === The interactions between the protein and ligand substantially affect the specificity between the two entities. Electrostatic interactions and Hydrophobic interactions are known to be the most influential in regards to where specificity between two molecules is derived from. The strength of these interactions between the protein and ligand often positively correlate with their specificity for one another. The specificity of a binding process is strongly dependent of the flexibility of the binding partners. A rigid protein is very restricted in its binding possibilities. A flexible protein can adapt its conformation to a larger number of ligands and thus is more promiscuous. As the binding process usually leads to a rigidification of both binding partners in the complex, binding of a flexible protein usually comes with an entropic penalty. This is the main reason for the frequently found positive correlation of binding affinity and binding specificity. Antibodies show a strong correlation between rigidity and specificity. This correlation extends far beyond the paratope of the antibodies
At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for US$2,000,000 and future milestone and royalty payments. Repligen has made several acquisitions through the early 2020s, including BioFlex Solutions and Tantti Laboratory Inc. among others. As of 2024, the company's President and Chief Executive Officer is Olivier Loeillot. As of 2025 it employs approximately 2,000 employees across several sites in the United States, Europe, and Asia.
Sources: en.wikipedia.org
As the number of confirmed COVID-19 cases in the state continued to rise, on March 15, Newsom urged people 65 and older and those with chronic health conditions to isolate themselves from others. He also called on bars and brewery and winery tasting rooms to close their doors to patrons. Some local jurisdictions had mandatory closures. The closures were extended to movie theaters and health clubs. He asked restaurants to stop serving meals inside their establishments and offer take-out meals only. His statewide stay-at-home order became mandatory on March 19. It limited in-house gatherings, including religious gatherings and Bible studies. It allowed movement outside the home for necessities or recreation, but people were required to maintain a safe distance apart. Activity "needed to maintain continuity of operation of the federal critical infrastructure sectors, critical government services, schools, childcare, and construction" was excluded from the order. Essential services such as grocery stores and pharmacies remained open. Newsom provided state funds to pay for protective measures such as hotel room lodging for hospital and other essential workers fearing returning home and infecting family members. By April 26, he had issued 30 executive orders under the state of emergency while the legislature had not been in session. On April 28, Newsom and the governors of Oregon and Washington announced a "shared approach" for reopening their economies.
In molecular biology, the insect pheromone-binding family A10/OS-D is a family of small helical proteins postulated to contribute to the specificity of the insect’s olfactory system by binding components of the natural pheromone mixtures. A class of small (14-20 Kd) water-soluble proteins, called pheromone binding proteins, first discovered in the insect sensillar lymph but also found in the mucus of vertebrates, is postulated to mediate the solubilisation of hydrophobic odorant molecules, and thereby to facilitate their transport to the receptor neurons. The product of a gene expressed in the olfactory system of Drosophila melanogaster (Fruit fly), OS-D, shares features common to vertebrate odorant binding proteins, but has a primary structure unlike odorant-binding proteins. OS-D derivatives have subsequently been found in chemosensory organs of phylogenetically distinct insects, including cockroaches, phasmids and moths, suggesting that OS-D-like proteins seem to be conserved in the insect phylum. OS-D and related proteins are members of the insect pheromone-binding family A10/OS-D.
Xylazine is widely used in veterinary medicine as a sedative, muscle relaxant, and analgesic. It is frequently used in the treatment of tetanus. It is not used in human medical treatment. Xylazine is similar to drugs such as phenothiazines, tricyclic antidepressants, and clonidine. As an anesthetic, it is typically used in conjunction with ketamine. In animals, xylazine may be administered intramuscularly, intravenously, and intraosseously. Subcutaneous, oral transmusocal and intranasal have been investigated but are not standard routes for xylazine administration. As a veterinary anesthetic, xylazine is typically only administered once for the intended effect before or during surgical procedures. α2-Adrenergic receptor antagonists such as atipamezole and yohimbine may be used to reverse the effects of xylazine in animals. Xylazine is licensed for use in non-meat horses. Off-label use in cattle is common with recommended withholding periods of 1–5 days for dairy cattle and 4–10 days for meat cattle. Cattle are more sensitive to xylazine than horses with the sensitivity being greater in meat cattle breeds than dairy cattle breeds. Xylazine's use in cats and dogs is being replaced with the more selective alpha2 adrenergic receptor agonists medetomidine and dexmedetomidine and in some countries xylazine is rarely used with cats and dogs. High amounts of catecholamines in a patient will require higher doses of xylazine to be administered to provide sedation. The heightened levels required may not be practical or possible to administer and regular doses may cause excitement.
=== Activation === PAR1 is activated when the terminal 41 amino acids of its N-terminus are cleaved by thrombin, a serine protease. Thrombin recognizes PAR1 by a Lysine-Aspartate-Proline-Arginine-Serine sequence at the N-terminal, where it cuts the peptide bond between Arginine-41 and Serine-42. The affinity of thrombin to this specific cleavage site in PAR1 is further aided by secondary interactions between thrombin's exosite and an acidic region of amino acid residues located C-terminal to Ser-42. This proteolytic cleavage is irreversible and the loose peptide, often referred to as parstatin, is then released outside of the cell. The newly revealed N-terminus acts as a tethered ligand that binds to a binding region between extracellular loops 3 and 4 of PAR1, therefore activating the protein. The binding instigates conformational changes in the protein that ultimately allow for the binding of G-proteins to sites on the intracellular region of PAR1.
Nazi architecture is a commonly cited example of architectural propaganda. Adolf Hitler was personally fascinated with ancient Rome, and Nazi architecture adopted elements from classical antiquity. Part of the Nazi cult involved the overpowering and subsuming of the individual into the greater German volk. This giving over of oneself to the whole was also expressed through Nazi architecture. The three primary expressed roles found in Nazi architecture are the (i)Theatrical, (ii)Symbolic, and (iii)Didactic, but each of these roles has its own place within the larger sphere of propaganda value.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.